Company intelligence / Profile preview

Raphael Holdings

Newark, New Jersey, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Rafael Holdings recently merged with Cyclo Therapeutics and now focuses on late-stage development of Trappsol Cyclo™, currently in a fully enrolled Phase III trial for Niemann-Pick Disease Type C1. Interim analysis results are expected mid–2025. The company also maintains interests in early-stage oncology/metabolism research through subsidiaries and investments.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Raphael Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raphael Holdings.

Explore the full profile